Lupin hopes a surge in demand for albuterol sulphate due to increased off-label use in COVID-19 patients will help its generic version, which is likely to be launched in the first half of FY21. But the Indian firm may recall a batch of metformin after the US FDA recently asked a few companies to retract extended-release versions due to NDMA concerns.
Off-label Use Of Albuterol For COVID-19 Has Upped Demand • Source: Shutterstock
Lupin Ltd. expects a shortage of albuterol sulphate in the US, caused by the drug's off-label use in COVID-19 patients, to aid sales of its generic to Teva Pharmaceutical Industries Ltd.’s Proair on launch.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
GNT Pharma prepares for the first listing of a Korean biotech on Nasdaq, while others sign major global out-licensing deals with large multinational partners.
With the FDA asking for another Phase III trial, the short bowel syndrome drug apraglutide could be years away from market, while the Linzess patent expiry and near-term debt loom.
The bispecific is the first in its class to record a Phase III survival win in small-cell lung cancer, although antibody-drug conjugates and other rivals could challenge in the coming years.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
